September 18, 2024 by McGill University Credit: Jonathan Gallego RudolfAmyloid-beta and tau proteins have long been associated with Alzheimer’s disease. The pathological buildup of these proteins leads to cognitive decline in people with the disease. How it does that, though, remains poorly understood. A new study from the labs of Sylvain Baillet at The Neuro...
September 13, 2024 by UK Research and Innovation Cells containing tau aggregates (green) before (left) and 13 hours after treatment with RING-nanobody (right). Credit: J. Benn – UK DRI at the University of CambridgeScientists have developed new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer’s disease, and improve symptoms of...
August 30, 2024 by Ernie Mundell In some people, new-onset depression may stem from the same buildup of toxic plaques in the brain that have long been linked to Alzheimer’s disease, according to a new study. “Our findings provide additional support for depressive symptoms as an early feature of preclinical Alzheimer’s disease,” wrote a team...
August 9, 2024 by Carmen Rotte, Max Planck Society Oligodendrocytes exhibit protein expression of amyloid precursor protein (APP) and an abundance of APP and BACE1 transcripts. Credit: Nature Neuroscience (2024). DOI: 10.1038/s41593-024-01730-3Memory loss, confusion, speech problems—Alzheimer’s disease is the most common cause of dementia, affecting about 35 million people worldwide, and the number is growing....
by Lori Solomon Increased glycated hemoglobin (HbA1c) stability within patient-specific target ranges is associated with a lower risk for Alzheimer’s disease and related dementias (ADRD), according to a study published online Aug. 2 in JAMA Network Open. Patricia C. Underwood, Ph.D., from the William F. Connell School of Nursing at Boston College, and colleagues examined...
July 30, 2024 by Washington University School of Medicine Determining performance of blood biomarker tests for amyloid pathology.Neurologists diagnose cognitive impairment with a clinical exam of memory and thinking skills. To determine whether Alzheimer’s disease is the cause of the cognitive impairment, evidence of the specific brain changes that characterize Alzheimer’s must be obtained, typically...
JULY 22, 2024 by Ingrid Fadelli , Medical Xpress Study overview. Credit: Nature Human Behaviour (2024). DOI: 10.1038/s41562-024-01924-6Recent advances in the study of proteomes (i.e., the entire range of proteins expressed by human cells and tissues) have opened new opportunities for identifying the biological markers of specific diseases or mental disorders. This could in turn...
JULY 12, 2024 by University of Cambridge Credit: Pixabay/CC0 Public DomainCambridge scientists have developed an artificially-intelligent tool capable of predicting in four cases out of five whether people with early signs of dementia will remain stable or develop Alzheimer’s disease. The team say this new approach could reduce the need for invasive and costly diagnostic...
Boston UniversityJun 25 2024 Trying to figure out whether someone has Alzheimer’s disease usually involves a battery of assessments-;interviews, brain imaging, blood and cerebrospinal fluid tests. But, by then, it’s probably already too late: memories have started slipping away, long established personality traits have begun subtly shifting. If caught early, new pioneering treatments can slow...
by University of Malaga Researchers identify a mutation that alters Alzheimer’s disease progression. The UMA coordinates this study, carried out by 100 multidisciplinary researchers from 50 different entities. Credit: University of MalagaThe scientist of the Faculty of Medicine of the University of Malaga José Luis Royo has coordinated a study that summarizes eight years of...
